Jan 05, 2017 13:01 pm UTC| Business
SALT LAKE CITY, Jan. 05, 2017 -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced plans to initiate a dosing flexibility (“DF”) study in addition to its previously announced dosing...
Jan 05, 2017 13:01 pm UTC| Business
SALT LAKE CITY, Jan. 05, 2017 -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced plans to initiate a dosing flexibility (“DF”) study in addition to its previously announced dosing...
Heat Biologics to Present at Biotech Showcase 2017 Conference in San Francisco
Jan 05, 2017 13:01 pm UTC| Business
DURHAM, N.C., Jan. 05, 2017 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s...
Heat Biologics to Present at Biotech Showcase 2017 Conference in San Francisco
Jan 05, 2017 13:01 pm UTC| Business
DURHAM, N.C., Jan. 05, 2017 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s...
Jan 05, 2017 13:00 pm UTC| Business
NEWARK, Calif., Jan. 05, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today...
Jan 05, 2017 13:00 pm UTC| Business
EXTON, Pa., Jan. 05, 2017 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U....
Jan 05, 2017 13:00 pm UTC| Business
SAN DIEGO, Jan. 05, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...